[go: up one dir, main page]

AU2001268154A1 - Indolinone derivatives as protein kinase/phosphatase inhibitors - Google Patents

Indolinone derivatives as protein kinase/phosphatase inhibitors

Info

Publication number
AU2001268154A1
AU2001268154A1 AU2001268154A AU6815401A AU2001268154A1 AU 2001268154 A1 AU2001268154 A1 AU 2001268154A1 AU 2001268154 A AU2001268154 A AU 2001268154A AU 6815401 A AU6815401 A AU 6815401A AU 2001268154 A1 AU2001268154 A1 AU 2001268154A1
Authority
AU
Australia
Prior art keywords
protein kinase
phosphatase inhibitors
indolinone derivatives
indolinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268154A
Inventor
G. Davis Harris
Xiaoyuan Li
Peng Cho Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU2001268154A1 publication Critical patent/AU2001268154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2001268154A 2000-06-02 2001-06-04 Indolinone derivatives as protein kinase/phosphatase inhibitors Abandoned AU2001268154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20916200P 2000-06-02 2000-06-02
US60/209,162 2000-06-02
PCT/US2001/017961 WO2001094312A2 (en) 2000-06-02 2001-06-04 Indolinone derivatives as protein kinase/phosphatase inhibitors

Publications (1)

Publication Number Publication Date
AU2001268154A1 true AU2001268154A1 (en) 2001-12-17

Family

ID=22777614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268154A Abandoned AU2001268154A1 (en) 2000-06-02 2001-06-04 Indolinone derivatives as protein kinase/phosphatase inhibitors

Country Status (6)

Country Link
US (2) US6706709B2 (en)
EP (1) EP1294688A2 (en)
JP (1) JP2003535847A (en)
AU (1) AU2001268154A1 (en)
CA (1) CA2410509A1 (en)
WO (1) WO2001094312A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035721A1 (en) * 2000-12-20 2004-07-07 Sugen Inc INDOLINONES 4-ARIL SUBSTITUTED; ITS PHARMACEUTICAL COMPOSITIONS AND METHOD TO MODULATE THE CATALYTIC ACTIVITY OF A PROTEIN KINASE
JP2004529110A (en) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
CA2506546A1 (en) 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7801585B1 (en) 2003-06-02 2010-09-21 Newlife Sciences Llc System for analyzing and treating abnormality of human and animal tissues
US7640052B2 (en) 2004-05-28 2009-12-29 Ippp, Llc Method of integrated proton beam and therapeutic magnetic resonance therapy
WO2005012241A2 (en) * 2003-07-25 2005-02-10 Novartis Ag p-38 KINASE INHIBITORS
GT200500321A (en) 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
WO2007056493A1 (en) * 2005-11-08 2007-05-18 Schumann Daniel H Device and method for the treatment of pain with electrical energy
ES2426448T3 (en) 2006-01-27 2013-10-23 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridin-4-one 2-indolinone protein kinase inhibitors
CN101007815B (en) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof
WO2007093616A1 (en) * 2006-02-15 2007-08-23 France Telecom Method and device for managing at least one group of users, corresponding computer program product
EP2068877A4 (en) * 2006-07-19 2011-09-21 Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
US8080252B2 (en) * 2006-07-19 2011-12-20 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
US8329686B2 (en) * 2006-08-29 2012-12-11 Washington University Isatin analogues and uses therefor
US20080109049A1 (en) * 2006-11-08 2008-05-08 Schumann Daniel H Device & method for relieving pain
WO2008138232A1 (en) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
WO2008138184A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
CN101367801B (en) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 Preparation method for pyrrol-hexahydric N heterocycle hydroxyl morpholine derivants, and medical uses thereof
US8299106B2 (en) * 2007-09-06 2012-10-30 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US20090149732A1 (en) * 2007-12-08 2009-06-11 Weinstock Ronald J System for use of electrical resonant frequencies in analyzing and treating abnormality of human and animal tissues
US20100324627A1 (en) * 2008-07-28 2010-12-23 Newlife Sciences, Llc Method and apparatus for resistivity measurement, detection and treatment in living tissue
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
JP5442906B2 (en) 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク Kinase inhibitor and method for treating cancer using the same
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
CA2819461A1 (en) 2010-11-30 2012-06-07 Newlife Sciences Llc Apparatus and method for treatment of pain with body impedance analyzer
EP3012248B1 (en) * 2013-06-20 2019-09-11 Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
CA2927612C (en) 2013-10-18 2022-08-30 University Health Network Treatment for pancreatic cancer
FR3030516B1 (en) * 2014-12-19 2019-12-27 Galderma Research & Development BICYCLE SULFONAMIDE DERIVATIVES AS INVERTED AGONISTS OF THE ORPHAN GAMMA RECEPTOR ASSOCIATED WITH ROR GAMMA (T) RETINOIDS
US20170057948A1 (en) * 2015-08-27 2017-03-02 Tallinn University Of Technology Indole-like trk receptor antagonists
EP3983051B1 (en) 2019-06-12 2024-12-18 Truerelief, LLC System for delivering pulsed electric current to living tissue
WO2021260722A1 (en) * 2020-06-21 2021-12-30 Translational Health Science And Technology Institute Design, synthesis of novel oxyindole inhibitors of denv rna dependent rna polymerase
US11911605B2 (en) 2021-03-05 2024-02-27 Truerelief Llc Method and apparatus for injury treatment
EP4650354A1 (en) * 2023-01-12 2025-11-19 Shenzhen Zhongge Biological Technology Co., Ltd. Indolone derivative having irak4 inhibitory activity, and preparation method therefor and use thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104796C (en) 1957-08-19
BE553661A (en) 1955-12-23
BE558210A (en) 1956-06-08
FR1398224A (en) 1964-05-06 1965-05-07 Ici Ltd Process for dyeing polyacrylonitrile textile materials
FR1599772A (en) 1968-09-17 1970-07-20
DE2159362A1 (en) 1971-11-30 1973-06-14 Bayer Ag Amino-3-(5-nitro-2-furfurylidene)oxindoles - with antibacterial and antimycotic activity
DE2159361A1 (en) 1971-11-30 1973-06-14 Bayer Ag Diacylamino-3-(5-nitro-2-furfurylidene) oxindoles - - with antibacterial and antimycotic activity
DE2159360A1 (en) 1971-11-30 1973-06-14 Bayer Ag Acylamino-3-(5-nitro-2-furfurylidene) oxindoles - with antibacterial and antimycotic activity
DE2159363A1 (en) 1971-11-30 1973-06-14 Bayer Ag Antimicrobial nitrofurans - useful eg as feed additives
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE3310891A1 (en) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim NEW INDOLINON (2) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS
DE3426419A1 (en) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim NEW OXINDOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, AND INTERMEDIATE PRODUCTS
JPS6229570A (en) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound
JPS6239564A (en) 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd Alpha-benzylidene-gamma-butyrolactone or gamma-butyrolactam derivative
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
JPS63141955A (en) 1986-12-03 1988-06-14 Kanegafuchi Chem Ind Co Ltd Tribenzylamine derivative
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
ES2108120T3 (en) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (en) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd Antitumor agent
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
FR2689397A1 (en) 1992-04-01 1993-10-08 Adir Use of di:tert-butyl-4-hydroxy-benzylidenyl-indoline-2-one - as an antioxidant, prostanoid synthesis inhibitor and platelet anti aggregant to treat atheroma, arteriosclerosis inflammatory diseases, etc.
FR2694004B1 (en) 1992-07-21 1994-08-26 Adir News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them.
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE59402281D1 (en) 1993-06-28 1997-05-07 Bayer Ag Bulk dyeing of plastics
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
RU2145852C1 (en) 1996-01-17 2000-02-27 Тайхо Фармасьютикал Ко., Лтд Inhibitor of intima hypertrophy, use of hydroxyindole derivative for synthesis of inhibitor of intima hypertrophy, compositions for inhibition of intima hypertrophy, method of prophylaxis and treatment of intima hypertrophy
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
WO1998007695A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
JP4713698B2 (en) 1997-03-05 2011-06-29 スージェン， インク． Formulation of hydrophobic drugs
ATE292623T1 (en) * 1997-05-07 2005-04-15 Sugen Inc 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ATIVITY
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6531502B1 (en) * 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
DE19816624A1 (en) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
CO5031249A1 (en) 1998-05-29 2001-04-27 Sugen Inc PIRROL SUBSTITUTE-2-PROTEINCI-NASAS INHIBITING INDOLINONES
DE19826940A1 (en) 1998-06-17 1999-12-23 Bayer Ag Substituted N-aryl-O-alkyl-carbamates
JP2002522452A (en) 1998-08-04 2002-07-23 スージェン・インコーポレーテッド Regulator of protein kinase 3-methylidenyl-2-indolinone
BR9916223A (en) 1998-12-17 2001-09-04 Hoffmann La Roche 4-aryloxindols as inhibitors of jnk protein kinases
ATE234830T1 (en) 1998-12-17 2003-04-15 Hoffmann La Roche 4-ALKENYL (AND ALKINYL)OXOINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, PARTICULARLY CDK2
KR20010087421A (en) 1998-12-17 2001-09-15 프리돌린 클라우스너, 롤란드 비. 보레르 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
MXPA01006742A (en) 1998-12-31 2004-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy.
US6689806B1 (en) * 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
JP2002540096A (en) * 1999-03-24 2002-11-26 スージェン・インコーポレーテッド Indolinone compounds as kinase inhibitors
ATE369359T1 (en) 2000-02-15 2007-08-15 Sugen Inc PYRROLE SUBSTITUTED INDOLIN-2-ONE PROTEIN KINASE INHIBITORS
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2004502686A (en) * 2000-06-30 2004-01-29 スージェン・インコーポレーテッド 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AR035721A1 (en) * 2000-12-20 2004-07-07 Sugen Inc INDOLINONES 4-ARIL SUBSTITUTED; ITS PHARMACEUTICAL COMPOSITIONS AND METHOD TO MODULATE THE CATALYTIC ACTIVITY OF A PROTEIN KINASE
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
US7071332B2 (en) 2006-07-04
JP2003535847A (en) 2003-12-02
CA2410509A1 (en) 2001-12-13
US6706709B2 (en) 2004-03-16
WO2001094312A2 (en) 2001-12-13
US20040147586A1 (en) 2004-07-29
US20020052369A1 (en) 2002-05-02
WO2001094312A3 (en) 2002-08-08
EP1294688A2 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2002234047A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002231166A1 (en) Pyrazole compounds useful as protein kinase inhibitors
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
IL182428A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
ZA200306335B (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2001249865A1 (en) Pyrazoles for inhibiting protein kinase
AU3770000A (en) Indolinone compounds as kinase inhibitors
AU2001234484A1 (en) Amide compounds for inhibiting protein kinases
AU6471300A (en) P38map kinase inhibitors
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AU5759899A (en) Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
AU2002357003A1 (en) Indoles as naaladase inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2002953255A0 (en) Protein kinase inhibitors
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
AU2576501A (en) Protein kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors